NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Cipla Reports 54.6% Decline in Net Profit for Q4FY26

Pharma major Cipla reported a net profit of ₹554.64 crore for the fourth quarter of FY26, a significant decline of 54.6% from ₹1,221.8 crore in the year-ago period. The company's financial performance has shown a notable dip, with a decrease in revenue for the quarter.

Cipla's revenue in Q4FY26 declined by 3% to ₹6,451.2 crore from ₹6,730 crore, year-on-year (YoY). This decline in revenue has contributed to the decrease in net profit for the company.

Financial PerformanceQ4FY26Q4FY25YoY Change
Net Profit₹554.64 crore₹1,221.8 crore-54.6%
Revenue₹6,451.2 crore₹6,730 crore-3%

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

In addition to the decline in financial performance, the company's Board of Directors also recommended a final dividend of ₹13 per equity share for the financial year ended 31st March, 2026. The dividend, upon declaration by the shareholders, will be paid within 30 days from the date of the Annual General Meeting.

The record date for the purpose of determining the eligible shareholders for the payment of final dividend has been set as 5 June 2026. At 12:48 PM, Cipla share price was trading 2.92% higher at ₹1,329.70 apiece on the BSE.

Investor Takeaway

Cipla's Q4 net profit declined by 54.6% YoY, and revenue slipped 3% YoY, indicating a challenging quarter for the company.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.